176 related articles for article (PubMed ID: 26885785)
1. Randomized, Double-Blind, Split-Face Study to Compare the Irritation Potential of Two Topical Acne Formulations Over a 21-Day Treatment Period.
Kircik LH; Bhatt V; Martin G; Pillai R
J Drugs Dermatol; 2016 Feb; 15(2):178-82. PubMed ID: 26885785
[TBL] [Abstract][Full Text] [Related]
2. Two Randomized, Double-Blind, Split-Face Studies to Compare the Irritation Potential of Two Topical Acne Fixed Combinations Over a 21-Day Treatment Period.
Bhatia N; Bhatt V; Martin G; Pillai R
J Drugs Dermatol; 2016 Jun; 15(6):721-6. PubMed ID: 27272079
[TBL] [Abstract][Full Text] [Related]
3. Randomized, observer-blind, split-face study to compare the irritation potential of 2 topical acne formulations over a 14-day treatment period.
Ting W
Cutis; 2012 Aug; 90(2):91-6. PubMed ID: 22988653
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene.
Goreshi R; Samrao A; Ehst BD
J Drugs Dermatol; 2012 Dec; 11(12):1422-6. PubMed ID: 23377511
[TBL] [Abstract][Full Text] [Related]
5. The tolerability profile of clindamycin 1%/benzoyl peroxide 5% gel vs. adapalene 0.1%/benzoyl peroxide 2.5% gel for facial acne: results of a randomized, single-blind, split-face study.
Gonzalez P; Vila R; Cirigliano M
J Cosmet Dermatol; 2012 Dec; 11(4):251-60. PubMed ID: 23174047
[TBL] [Abstract][Full Text] [Related]
6. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy and tolerability of treatment in moderate to severe acne.
Callender VD
J Drugs Dermatol; 2012 May; 11(5):643-8. PubMed ID: 22527435
[TBL] [Abstract][Full Text] [Related]
7. Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator-masked, controlled trial.
Capizzi R; Landi F; Milani M; Amerio P
Br J Dermatol; 2004 Aug; 151(2):481-4. PubMed ID: 15327558
[TBL] [Abstract][Full Text] [Related]
8. Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in the treatment of acne vulgaris in patients aged ≥ 12 years.
Keating GM
Am J Clin Dermatol; 2011 Dec; 12(6):407-20. PubMed ID: 21967116
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations.
Webster G; Rich P; Gold MH; Mraz S; Calvarese B; Chen D
J Drugs Dermatol; 2009 Aug; 8(8):736-43. PubMed ID: 19663111
[TBL] [Abstract][Full Text] [Related]
10. Treatment of moderate to severe acne vulgaris in a Hispanic population: a post-hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel.
Cook-Bolden FE
J Drugs Dermatol; 2012 Apr; 11(4):455-9. PubMed ID: 22453581
[TBL] [Abstract][Full Text] [Related]
11. How patients experience and manage dryness and irritation from acne treatment.
Feldman SR; Chen DM
J Drugs Dermatol; 2011 Jun; 10(6):605-8. PubMed ID: 21637901
[TBL] [Abstract][Full Text] [Related]
12. Fixed Combination of Clindamycin Phosphate 1.2% and Benzoyl Peroxide 3.75% Aqueous Gel: Long-Term Use in Adult Females With Moderate Acne Vulgaris.
Kircik LH
J Drugs Dermatol; 2017 Jun; 16(6):543-546. PubMed ID: 28686771
[TBL] [Abstract][Full Text] [Related]
13. Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, active-controlled, parallel-group study.
Kawashima M; Hashimoto H; Alió Sáenz AB; Ono M; Yamada M
Br J Dermatol; 2015 Feb; 172(2):494-503. PubMed ID: 25040180
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled double-blinded split-face prospective clinical trial to assess the efficacy, safety, and tolerability of a novel 3-step routine compared to benzoyl peroxide for the treatment of mild to moderate acne vulgaris.
Gern A; Walter J; Xu S; Vakharia PP
Arch Dermatol Res; 2024 May; 316(6):230. PubMed ID: 38787441
[TBL] [Abstract][Full Text] [Related]
15. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris.
Pariser DM; Rich P; Cook-Bolden FE; Korotzer A
J Drugs Dermatol; 2014 Sep; 13(9):1083-9. PubMed ID: 25226009
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with adapalene-benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study.
Dréno B; Kaufmann R; Talarico S; Torres Lozada V; Rodríguez-Castellanos MA; Gómez-Flores M; De Maubeuge J; Berg M; Foley P; Sysa-Jedrzejowska A; Kerrouche N; Paliargues F; Bettoli V
Br J Dermatol; 2011 Aug; 165(2):383-90. PubMed ID: 21495995
[TBL] [Abstract][Full Text] [Related]
17. Randomized tolerability analysis of clindamycin phosphate 1.2%-tretinoin 0.025% gel used with benzoyl peroxide wash 4% for acne vulgaris.
Draelos ZD; Potts A; Alió Saenz AB;
Cutis; 2010 Dec; 86(6):310-8. PubMed ID: 21284283
[TBL] [Abstract][Full Text] [Related]
18. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris.
Langner A; Chu A; Goulden V; Ambroziak M
Br J Dermatol; 2008 Jan; 158(1):122-9. PubMed ID: 18047518
[TBL] [Abstract][Full Text] [Related]
19. Adapalene-benzoyl peroxide once-daily, fixed-dose combination gel for the treatment of acne vulgaris: a randomized, bilateral (split-face), dose-assessment study of cutaneous tolerability in healthy participants.
Andres P; Pernin C; Poncet M
Cutis; 2008 Mar; 81(3):278-84. PubMed ID: 18441854
[TBL] [Abstract][Full Text] [Related]
20. The efficacy, safety, and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris: a randomized trial.
Babaeinejad SH; Fouladi RF
J Drugs Dermatol; 2013 Jul; 12(7):790-4. PubMed ID: 23884492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
